Company Monitoring Page for AbbVie

latest headlines for company on cafepharma

AbbVie's JAK-1 inhibitor hits the mark in Crohn's disease
BioPharma Dive
Thu, 05/11/17 - 11:17 am
Tags:
AbbVie, JAK inhibitors, Crohn's Disease, Upadacitinib
Gilead Vs. AbbVie: A DGI Thunderdome Match
Seeking Alpha
Mon, 05/8/17 - 09:55 pm
Tags:
Gilead Sciences, AbbVie
AbbVie Is Focused on Label Expansion of Imbruvica in 2017
Market Realist
Tue, 05/2/17 - 11:22 am
Tags:
AbbVie, Imbruvica, non-Hodgkin's lymphoma, mantle cell lymphoma, graft vs host disease
AbbVie Reports Humira Sales Growth in 1st Quarter
Yahoo/GuruFocus
Sun, 04/30/17 - 12:49 pm
Tags:
AbbVie, Humira, earnings
These 7 Drugmakers Relied on Price Hikes for 100% of Their Earnings Growth in 2016
Motley Fool
Sat, 04/29/17 - 10:12 am
Tags:
earnings, drug pricing, Biogen, Eli Lilly, AbbVie, Allergan, Merck, Pfizer, Amgen
AbbVie stock surges 1.5% after first-quarter profit, revenue beats
Marketwatch
Thu, 04/27/17 - 09:42 am
Tags:
AbbVie, earnings
Q1 Earnings Preview: AbbVie, AstraZeneca, BMS, Celgene, Roche, Sanofi
BioPharma Dive
Wed, 04/26/17 - 09:29 pm
Tags:
earnings, AbbVie, AstraZeneca, Bristol-Myers Squibb, Celgene, Roche, Sanofi
Failure Of Abbvie's Cancer Drug Hasn't Hurt The Stock
Barron's
Fri, 04/21/17 - 11:28 am
Tags:
AbbVie, veliparib
AbbVie, Enanta post stellar hep C PhIII data, but no one is cheering
Endpoints
Thu, 04/20/17 - 08:52 pm
Tags:
AbbVie, Enanta, hepatitis C, glecaprevir/pibrentasvir
Report: Price hikes are still driving pharma's earnings growth. Who's most at risk?
Fierce Pharma
Wed, 04/19/17 - 04:21 pm
Tags:
earnings, drug pricing, Bristol-Myers Squibb, AbbVie, Roche
Lilly and Incyte's Loss Is AbbVie and Regeneron's Gain
Motley Fool
Mon, 04/17/17 - 12:07 pm
Tags:
Eli Lilly, Inctye, AbbVie, Regeneron, rheumatoid arthritis, FDA, baricitinib, Humira
Lilly, Pfizer, et al. back Sanofi and Regeneron in PCSK9 patent appeal. AbbVie doesn't
Fierce Pharma
Tue, 04/4/17 - 12:13 am
Tags:
Eli Lilly, Pfizer, Sanofi, AbbVie, Regeneron, patents, PCSK9 inhibitors, Repatha
Pharma's most-valuable brands? J&J, Pfizer and Merck. Valeant, not so much
Fierce Pharma
Sat, 04/1/17 - 08:14 am
Tags:
JNJ, Pfizer, Merck, AbbVie, Eli Lilly, Bristol-Myers Squibb
How AbbVie Is Attacking Tumors at Their Roots
Motley Fool
Wed, 03/29/17 - 09:06 am
Tags:
AbbVie, solid tumors, cancer, stem cells, Stemcentrx, Rova-T
3 Things You Probably Didn't Know About AbbVie Inc.
Motley Fool
Tue, 03/28/17 - 10:16 am
Tags:
AbbVie, dividends, debt
AbbVie's Hepatitis C Treatment Under Priority Review in Japan
Yahoo/GuruFocus
Wed, 03/15/17 - 09:47 pm
Tags:
AbbVie, hepatitis C, Japan, glecaprevir/pibrentasvir
AbbVie chief's $20M-plus pay—and company jet-setting—headed skyward in 2016
Fierce Pharma
Fri, 03/10/17 - 09:53 am
Tags:
AbbVie, Pharma CEOs, executive pay, Richard Gonzalez
2016 went out like a lamb in the biopharma M&A world. Will it roar back in 2017? Plus, top 10 deals
Endpoints
Wed, 02/22/17 - 11:43 am
Tags:
M&A, Shire, Baxalta, Pfizer, Medivation, Mylan, Meda, AbbVie, Stemcentrx, Anacor
AbbVie Announces $5 Billion Increase to Stock Repurchase Program
Yahoo
Sat, 02/18/17 - 02:22 pm
Tags:
AbbVie, stock buyback
Pfizer says rheumatoid arthritis drug is comparable to Humira as combination treatment but not alone
Marketwatch
Thu, 02/16/17 - 03:13 pm
Tags:
Pfizer, Xeljanz, AbbVie, Humira, rheumatoid arthritis

Pages

last 30 twitter posts

current feelings about your job

Please rate how you feel about your job this moment. 1 = "I hate my job" and 7 = "I love my job"
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Fill in the blank.